Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study discovered that the disposition of LY191704 enantiomers in rats and dogs is both stereoselective and species specific.

This study found that Rosebay extract significantly reduced dandruff and sebum production, suggesting it may be an effective anti-dandruff ingredient as a complement or alternative to antifungal treatments.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This study found that combining shikimic acid with Prunus mume fruit extract significantly reduces type I 5α-reductase levels in testosterone-stressed skin sebocytes, surpassing the effects of shikimic acid or standard acne treatments alone, and shows promise for stable, non-irritating acne remedies in cosmetic formulations.

This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.

This study reports that the compound CS-891 can inhibit 5alpha-reductase activity in the dermal papillae of human hair follicles, suggesting potential for treating androgenetic alopecia.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

In this study, fraction No. 3 of Oryza sativa bran extract demonstrated high unsaturated fatty acid content and significant 5α-reductase inhibition, suggesting potential for developing anti-androgenic alopecia products.

This review discusses the role of DHT in male sexual differentiation and fertility in individuals with 5α-reductase-2 deficiency, reporting no new clinical results.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This study found that among 17 beta-(N-ureylene-N,N'-disubstituted)-4-azasteroids, those with an N'-phenyl moiety were the most effective inhibitors of human type I 5 alpha-reductase.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.

This review discusses the role of steroid 5 alpha reductase 2 in converting testosterone to DHT and its association with conditions like benign prostatic hyperplasia and prostate cancer; it reports no new results.

This study suggests that 9-Octadecenoic acid (Z)-, 2,3-dihydroxypropyl ester from African Yam bean seeds may inhibit the human 5α-reductase II enzyme, potentially helping manage BPH, although further studies are needed.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

This study found that certain compounds from Chaga mushrooms stimulated the proliferation of human hair follicle cells more effectively than minoxidil, suggesting potential for hair-growth treatments.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

This study found that certain pyrazole derivatives may serve as effective 5α-reductase inhibitors with potential use in the treatment of androgenetic alopecia, based on molecular docking analyses.

In this study, manipulation of the enzyme 5α-reductase type 2 in human hepatocytes altered lipogenesis, suggesting clinical implications for patients using 5α-reductase inhibitors by affecting glucocorticoid action on hepatic lipid metabolism.